Biotech · Private company · Union, NJ, US

Kathera Bioscience Inc.

Track this companyFree. Adds Kathera Bioscience Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials0None registered

Pipeline programs0None found yet

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

NIH awards4

Novel Broad Spectrum Inhibitors of Dihydrofolate Reductase (DHFR) for Treatment of Infections from High Threat Fungal PathogensFiscal year 2026 · $995.1KNIH RePORTER 5R44AI181163-03 · fetched Nov 12, 2026
Novel Broad Spectrum Inhibitors of Dihydrofolate Reductase (DHFR) for Treatment of Infections from High Threat Fungal PathogensFiscal year 2025 · $995.1KNIH RePORTER 4R44AI181163-02 · fetched Nov 12, 2026
Novel Broad Spectrum Inhibitors of Dihydrofolate Reductase (DHFR) for Treatment of Infections from High Threat Fungal PathogensFiscal year 2024 · $298.5KNIH RePORTER 1R44AI181163-01 · fetched Nov 12, 2026
A Redesigning Existing Drugs against Indispensable Targets (ReEDIT) platform technology for discovery of novel drugs to treat fungal infectionsFiscal year 2024 · $298.5KNIH RePORTER 5R43AI170288-02 · fetched Nov 12, 2026